CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
软组织肉瘤的免疫治疗：抗 PD1/PDL1 及 beyond
英文原题：Immunotherapy for Soft Tissue Sarcomas: Anti-PD1/PDL1 and Beyond.
查看英文原题
Immunotherapy for Soft Tissue Sarcomas: Anti-PD1/PDL1 and Beyond.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
肉瘤是一组异质性间叶源性恶性肿瘤，包括150多种不同亚型。尽管这些肿瘤的分子特征得到了更好的表征，且分子驱动的治疗策略也有所发展，但大多数肉瘤仍为侵袭性肿瘤，晚期预后较差。在过去十年中，免疫治疗已发展用于治疗晚期癌症，主要得益于免疫检查点抑制剂（ICI），如抗PD1/PDL1，以及后来的过继性免疫细胞治疗。在本综述中，我们旨在总结软组织肉瘤（STS）免疫治疗的现状。总体而言，纳入多种STS亚型的ICI临床试验报告的疗效有限，仅有少数离群应答者。两种新兴生物标志物在筛选合适候选患者和开发联合治疗方面均具有意义。最后，创新性过继疗法在STS中近期的突破似乎极具前景。
展开英文摘要原文
Sarcomas gather a heterogeneous group of mesenchymal malignant tumors including more than 150 different subtypes. Most of them represent aggressive tumors with poor prognosis at the advanced stage, despite the better molecular characterization of these tumors and the development of molecular-driven therapeutic strategies.
During the last decade, immunotherapy has been developed to treat advanced cancers, mainly thanks to immune checkpoint inhibitors (ICI) such as anti-PD1/PDL1 and later to adoptive immune cell therapies. In this review, we aim to summarize the state of the art of immunotherapy in soft tissue sarcomas (STS).
Overall, the clinical trials of ICI that included a wide diversity of STS subtypes reported limited efficacy with some outlying responders. Both emerging biomarkers are of interest in selecting good candidates and in the development of combination therapies.
Finally, the recent breakthroughs of innovative adoptive therapies in STS seem highly promising.
论文信息
- 作者
- Fazel M、Dufresne A、Vanacker H、Waissi W、Blay JY、Brahmi M
- 单位
- Centre Léon Bérard, 28 Rue Laënnec, 69008 Lyon, France.France
- 文献类型
- 综述
- 期刊
- Cancers2023 Mar 7
- 原文标识
- PubMed 36980528 · DOI 10.3390/cancers15061643
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →